Join the Cardiovascular Risk Reduction group to help and get support from people like you.
Cardiovascular Risk Reduction News (Page 18)
Pitavastatin Cuts Risk of Cardiovascular Events in Patients With HIV
TUESDAY, July 25, 2023 – For patients with HIV infection, those receiving pitavastatin have reduced risk of major adverse cardiovascular events over a median follow-up of 5.1 years, according to a...
FDA Approves Lodoco (colchicine) as the First Anti-Inflammatory Drug for Cardiovascular Disease
Parsippany, NJ – June 20, 2023 – AGEPHA Pharma USA, LLC, today announced that, following a Priority Review, the U.S. Food and Drug Administration (FDA) has approved Lodoco® as the first anti...
Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients
May 9, 2023 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) ...
Brilinta Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease
June 1, 2020 – AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most ...
FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease
PLAINSBORO, N.J., Jan. 16, 2020 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic (semaglutide) injection 0.5 mg...
FDA Approves Vascepa (icosapent ethyl) to Reduce Cardiovascular Risk
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 13, 2019 (GLOBE NEWSWIRE) – Amarin Corporation plc (NASDAQ: AMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new...
FDA Approves Praluent (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization
PARIS and TARRYTOWN, NY – April 26, 2019 – The U.S. Food and Drug Administration (FDA) has approved Praluent (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hos...
FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
TITUSVILLE, NJ, October 30, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Invokana (canagliflozin) to r...
FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
TITUSVILLE, NJ, October 11, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to r...
FDA Approves Amgen's Repatha (evolocumab) to Prevent Heart Attack and Stroke
THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug...
Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular...
FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes
December 2, 2016 – The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2...
FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack
Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...
FDA Approves Entresto (sacubitril/valsartan) for Heart Failure
July 7, 2015 – The U.S. Food and Drug Administration today approved Entresto (sacubitril/valsartan) tablets for the treatment of heart failure. The drug has been shown to reduce the rate of...
FDA Approves Zontivity to Reduce the Risk of Heart Attacks and Stroke
May 8, 2014 – The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Prevention of Cardiovascular Disease
Related drug support groups
Xarelto, Ozempic, Victoza, simvastatin, Wegovy, Repatha, Trulicity, semaglutide, Brilinta, ramipril, Jardiance, liraglutide, Invokana, ticagrelor